PMID- 30216977
OWN - NLM
STAT- MEDLINE
DCOM- 20190102
LR  - 20190102
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 19
IP  - 9
DP  - 2018 Sep 13
TI  - The Anti-Inflammatory Effects of Vitamin D in Tumorigenesis.
LID - 10.3390/ijms19092736 [doi]
LID - 2736
AB  - In conjunction with the classical functions of regulating intestinal, bone, and 
      kidney calcium and phosphorus absorption, as well as bone mineralization of 
      vitamin D, the population-based association between low vitamin D status and 
      increased cancer risk is now generally accepted. Inflammation is causally related 
      to oncogenesis. It is widely thought that vitamin D plays an important role in 
      the modulation of the inflammation system by regulating the production of 
      inflammatory cytokines and immune cells, which are crucial for the pathogenesis 
      of many immune-related diseases. Mechanistic studies have shown that vitamin D 
      influences inflammatory processes involved in cancer progression, including 
      cytokines, prostaglandins, MAP kinase phosphatase 5 (MKP5), the nuclear factor 
      kappa B (NF-kappaB) pathway, and immune cells. Multiple studies have shown that 
      vitamin D has the potential to inhibit tumor development by interfering with the 
      inflammation system. The present review summarizes recent studies of the 
      mechanisms of vitamin D on regulating the inflammation system, which contributes 
      to its potential for cancer prevention and therapy. This review helps answer 
      whether inflammation mediates a causal relationship between vitamin D and 
      tumorigenesis.
FAU - Liu, Wei
AU  - Liu W
AD  - College of Laboratory Medicine, Jilin Medical University, Jilin 132013, China. 
      liuweijldx@sina.com.
AD  - Laboratory of Antibody Engineering, Jilin Medical University, Jilin 132013, 
      China. liuweijldx@sina.com.
FAU - Zhang, Lei
AU  - Zhang L
AD  - College of Laboratory Medicine, Jilin Medical University, Jilin 132013, China. 
      zhanglei0358@sina.com.
AD  - Laboratory of Antibody Engineering, Jilin Medical University, Jilin 132013, 
      China. zhanglei0358@sina.com.
FAU - Xu, Hui-Jing
AU  - Xu HJ
AD  - College of Laboratory Medicine, Jilin Medical University, Jilin 132013, China. 
      renyunqingzheng@126.com.
AD  - Laboratory of Antibody Engineering, Jilin Medical University, Jilin 132013, 
      China. renyunqingzheng@126.com.
FAU - Li, Yan
AU  - Li Y
AD  - College of Laboratory Medicine, Jilin Medical University, Jilin 132013, China. 
      jlliyang2004@163.com.
AD  - Laboratory of Antibody Engineering, Jilin Medical University, Jilin 132013, 
      China. jlliyang2004@163.com.
FAU - Hu, Chuan-Min
AU  - Hu CM
AD  - Laboratory of Antibody Engineering, Jilin Medical University, Jilin 132013, 
      China. chuminhu@163.com.
FAU - Yang, Jing-Yan
AU  - Yang JY
AD  - Department of Physical Education, Jilin Medical University, Jilin 132013, China. 
      yjy8899@126.com.
FAU - Sun, Mei-Yan
AU  - Sun MY
AUID- ORCID: 0000-0002-5015-1224
AD  - College of Laboratory Medicine, Jilin Medical University, Jilin 132013, China. 
      sunmy990@163.com.
AD  - Laboratory of Antibody Engineering, Jilin Medical University, Jilin 132013, 
      China. sunmy990@163.com.
LA  - eng
GR  - 81601234/National Natural Science Foundation of China/
GR  - 81771304/National Natural Science Foundation of China/
GR  - 201750246/the Science and Technology Innovation Development Fund of Jilin City/
PT  - Journal Article
PT  - Review
DEP - 20180913
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (NF-kappa B)
RN  - 1406-16-2 (Vitamin D)
RN  - EC 3.1.3.16 (DUSP10 protein, human)
RN  - EC 3.1.3.16 (Mitogen-Activated Protein Kinase Phosphatases)
RN  - EC 3.1.3.48 (Dual-Specificity Phosphatases)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/immunology/*therapeutic use
MH  - Carcinogenesis/*drug effects/*immunology
MH  - Dual-Specificity Phosphatases/metabolism
MH  - Humans
MH  - Inflammation/prevention & control
MH  - Mitogen-Activated Protein Kinase Phosphatases/metabolism
MH  - NF-kappa B/metabolism
MH  - Vitamin D/immunology/*therapeutic use
PMC - PMC6164284
OTO - NOTNLM
OT  - cytokines
OT  - immune cells
OT  - inflammation
OT  - tumorigenesis
OT  - vitamin D
COIS- The authors declare no conflicts of interest.
EDAT- 2018/09/16 06:00
MHDA- 2019/01/03 06:00
PMCR- 2018/09/01
CRDT- 2018/09/16 06:00
PHST- 2018/07/18 00:00 [received]
PHST- 2018/09/07 00:00 [revised]
PHST- 2018/09/08 00:00 [accepted]
PHST- 2018/09/16 06:00 [entrez]
PHST- 2018/09/16 06:00 [pubmed]
PHST- 2019/01/03 06:00 [medline]
PHST- 2018/09/01 00:00 [pmc-release]
AID - ijms19092736 [pii]
AID - ijms-19-02736 [pii]
AID - 10.3390/ijms19092736 [doi]
PST - epublish
SO  - Int J Mol Sci. 2018 Sep 13;19(9):2736. doi: 10.3390/ijms19092736.